A new report has speculated that gene therapies that aim to cure hemophilia could come with a price tag of $1.5 million or more.
According to the research note, put together by analysts at Leerink, the new gene therapies for hemophilia are currently being developed by BioMarin, Spark Therapeutics and UniQure. The goal is that the new treatments will entirely cure or significantly improve hemophilia, an inherited blood disorder that affects about 20,000 Americans, in one dose.
Although the cost would set a new threshold for drug pricing, it would also be a better deal than the current $580,000-$800,000-a-year cost to treat hemophilia.
Read the full CNBC report.